{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:16Z","timestamp":1790889916588,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09130-6","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:00:39Z","timestamp":1767492039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Baseline Blood Eosinophil Count for Identifying Superior Responders to Biologics in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"69","author":[{"given":"Yang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congxian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"issue":"4","key":"9130_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","volume":"4","author":"WW Stevens","year":"2016","unstructured":"Stevens WW, Schleimer RP, Kern RC (2016) Chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunology: Pract 4(4):565\u2013572","journal-title":"J Allergy Clin Immunology: Pract"},{"issue":"5","key":"9130_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/all.15982","volume":"79","author":"PW Hellings","year":"2023","unstructured":"Hellings PW, Alobid I, Anselmo-Lima WT et al (2023) EUFOREA\/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care. Allergy 79(5):1123\u20131133","journal-title":"Allergy"},{"issue":"0","key":"9130_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"0","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ, Lund VJ, Hopkins C et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology J 0(0):1\u2013464","journal-title":"Rhinology J"},{"issue":"3","key":"9130_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","volume":"145","author":"C Bachert","year":"2020","unstructured":"Bachert C, Zhang N, Cavaliere C et al (2020) Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 145(3):725\u2013739","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"9130_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jaci.2025.03.011","volume":"155","author":"R Kratchmarov","year":"2025","unstructured":"Kratchmarov R, Dharia T, Buchheit K (2025) Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 155(5):1401\u20131410","journal-title":"J Allergy Clin Immunol"},{"key":"9130_CR6","doi-asserted-by":"crossref","unstructured":"Fokkens WJ, Viskens AS, Backer V et al (2023) EPOS\/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology 61(3):194-202","DOI":"10.4193\/Rhin22.489"},{"issue":"5","key":"9130_CR7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/all.16519","volume":"80","author":"M Xian","year":"2025","unstructured":"Xian M, Yan B, Song X et al (2025) Chinese position paper on biologic therapy for chronic rhinosinusitis with nasal polyps. Allergy 80(5):1208\u20131225","journal-title":"Allergy"},{"issue":"5","key":"9130_CR8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/coa.13793","volume":"46","author":"B Yang","year":"2021","unstructured":"Yang B, Dziadzio M, Meridamorillas M et al (2021) Chronic rhinosinusitis: eosinophil blood reference values and decision limits and tissue count intravariability. Clin Otolaryngol 46(5):1142\u20131145","journal-title":"Clin Otolaryngol"},{"issue":"6","key":"9130_CR9","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","volume":"27","author":"D Luo","year":"2016","unstructured":"Luo D, Wan X, Liu J, Tong T (2016) Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Stat Methods Med Res 27(6):1785\u20131805","journal-title":"Stat Methods Med Res"},{"key":"9130_CR10","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14(1):135","DOI":"10.1186\/1471-2288-14-135"},{"issue":"10482","key":"9130_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","volume":"405","author":"P Gevaert","year":"2025","unstructured":"Gevaert P, Desrosiers M, Cornet M et al (2025) Efficacy and safety of twice per year Depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials. Lancet 405(10482):911\u2013926","journal-title":"Lancet"},{"issue":"1","key":"9130_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/19458924211030486","volume":"36","author":"C Damask","year":"2021","unstructured":"Damask C, Chen M, Holweg CTJ et al (2021) Defining the efficacy of Omalizumab in nasal polyposis: A POLYP 1 and POLYP 2 subgroup analysis. Am J Rhinol Allergy 36(1):135\u2013141","journal-title":"Am J Rhinol Allergy"},{"key":"9130_CR13","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 54(10):1046\u20131055","DOI":"10.1136\/bmj.l4898"},{"issue":"7109","key":"9130_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"issue":"10","key":"9130_CR15","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JAC Sterne","year":"2001","unstructured":"Sterne JAC, Egger M (2001) Funnel plots for detecting bias in meta-analysis. J Clin Epidemiol 54(10):1046\u20131055","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"9130_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64(4):383\u2013394","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"9130_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/j.1398-9995.2009.01973.x","volume":"64","author":"JL Brozek","year":"2009","unstructured":"Brozek JL, Akl EA, Alonso-Coello P et al (2009) Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 64(5):669\u2013677","journal-title":"Allergy"},{"issue":"1","key":"9130_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12874-018-0483-0","volume":"18","author":"CJ Weir","year":"2018","unstructured":"Weir CJ, Butcher I, Assi V et al (2018) Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review. BMC Med Res Methodol 18(1):25","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"9130_CR19","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","volume":"392","author":"BJ Lipworth","year":"2025","unstructured":"Lipworth BJ, Han JK, Desrosiers M et al (2025) Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med 392(12):1178\u20131188","journal-title":"N Engl J Med"},{"issue":"10","key":"9130_CR20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK, Bachert C, Fokkens W et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153","journal-title":"Lancet Respir Med"},{"issue":"5","key":"9130_CR21","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","volume":"149","author":"C Bachert","year":"2022","unstructured":"Bachert C, Sousa AR, Han JK et al (2022) Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol 149(5):1711\u20131721e1716","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"9130_CR22","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/alr.23249","volume":"14","author":"C Bachert","year":"2024","unstructured":"Bachert C, Khan AH, Lee SE et al (2024) Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52. Int Forum Allergy Rhinol 14(3):668\u2013678","journal-title":"Int Forum Allergy Rhinol"},{"key":"9130_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2147\/JAA.S391896","volume":"16","author":"WW Busse","year":"2023","unstructured":"Busse WW, Pavord ID, Siddiqui S et al (2023) Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma irrespective of baseline asthma characteristics. J Asthma Allergy 16:411\u2013419","journal-title":"J Asthma Allergy"},{"key":"9130_CR24","doi-asserted-by":"publisher","first-page":"102076","DOI":"10.1016\/j.eclinm.2023.102076","volume":"61","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Yan B, Shen S et al (2023) Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine 61:102076","journal-title":"EClinicalMedicine"},{"key":"9130_CR25","doi-asserted-by":"crossref","unstructured":"Shen S, Yan B, Wang M et al (2025) Stapokibart for severe uncontrolled chronic rhinosinusitis with nasal polyps. Jama-J Am Med Assoc 334(11):962\u2013972","DOI":"10.1001\/jama.2025.12515"},{"issue":"3","key":"9130_CR26","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM et al (2021) Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunology: Pract 9(3):1133\u20131141","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"9130_CR27","doi-asserted-by":"crossref","unstructured":"Bachert C, Hicks A, Gane S et al (2024) The interleukin-4\/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps. Front Immunol 15:1356298","DOI":"10.3389\/fimmu.2024.1356298"},{"issue":"4","key":"9130_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jaci.2023.06.005","volume":"152","author":"S Siddiqui","year":"2023","unstructured":"Siddiqui S, Bachert C, Bjermer L et al (2023) Eosinophils and tissue remodeling: relevance to airway disease. J Allergy Clin Immunol 152(4):841\u2013857","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"9130_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/alr.22994","volume":"12","author":"P Gevaert","year":"2022","unstructured":"Gevaert P, Han JK, Smith SG et al (2022) The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinology 12(11):1413\u20131423","journal-title":"Int Forum Allergy Rhinology"},{"issue":"11","key":"9130_CR30","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/all.12010","volume":"67","author":"R Pezato","year":"2012","unstructured":"Pezato R, \u015awierczy\u0144ska-Kr\u0119pa M, Ni\u017cankowska\u2010Mogilnicka E et al (2012) Role of imbalance of eicosanoid pathways and Staphylococcal superantigens in chronic rhinosinusitis. Allergy 67(11):1347\u20131356","journal-title":"Allergy"},{"issue":"10","key":"9130_CR31","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/lary.26555","volume":"127","author":"J Lavin","year":"2017","unstructured":"Lavin J, Min JY, Lidder AK et al (2017) Superior turbinate eosinophilia correlates with olfactory deficit in chronic rhinosinusitis patients. Laryngoscope 127(10):2210\u20132218","journal-title":"Laryngoscope"},{"key":"9130_CR32","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.waojou.2023.100776","volume":"16","author":"J Braid","year":"2023","unstructured":"Braid J, Islam L, Gugiu C, Omachi TA, Doll H (2023) Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps. World Allergy Organ J 16:100776. https:\/\/doi.org\/10.1016\/j.waojou.2023.100776","journal-title":"World Allergy Organ J"},{"key":"9130_CR33","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME et al (2022) Effect of dupilumab on blood eosinophil counts in patients with Asthma, chronic rhinosinusitis with nasal Polyps, atopic Dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract 10:2695\u20132709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"9130_CR34","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394:1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"2","key":"9130_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jaci.2023.09.041","volume":"153","author":"J Yu","year":"2024","unstructured":"Yu J, Yan B, Shen S et al (2024) IgE directly affects eosinophil migration in chronic rhinosinusitis with nasal polyps through CCR3 and predicts the efficacy of Omalizumab. J Allergy Clin Immunol 153(2):447\u2013460e449","journal-title":"J Allergy Clin Immunol"},{"key":"9130_CR36","doi-asserted-by":"crossref","unstructured":"Sima Y, Zheng M, Zhao Y et al (2025) Predicting the effectiveness of Omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers. World Allergy Organ J 18(1):101009","DOI":"10.1016\/j.waojou.2024.101009"},{"issue":"10","key":"9130_CR37","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1111\/all.16189","volume":"79","author":"C Bachert","year":"2024","unstructured":"Bachert C, Gevaert P, Lipworth B et al (2024) Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis. Allergy 79(10):2858\u20132861","journal-title":"Allergy"},{"issue":"12","key":"9130_CR38","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1111\/all.14582","volume":"75","author":"H Breiteneder","year":"2020","unstructured":"Breiteneder H, Peng YQ, Agache I et al (2020) Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy 75(12):3039\u20133068","journal-title":"Allergy"},{"issue":"1","key":"9130_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","volume":"76","author":"I Agache","year":"2020","unstructured":"Agache I, Akdis CA, Akdis M et al (2020) EAACI biologicals Guidelines\u2014Recommendations for severe asthma. Allergy 76(1):14\u201344","journal-title":"Allergy"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09130-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09130-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09130-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:00:41Z","timestamp":1767492041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09130-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9130"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09130-6","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"After publication, all data in this article can be obtained by contacting the corresponding author. E-mail: superzhang013@163.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT-5.0 and DeepSeek tools to review grammatical accuracy, thereby enhancing the readability and fluency of the text. After using these tools, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI and AI-assisted Technologies in the Manuscript Preparation Process"}}],"article-number":"1"}}